Evaluation of anti-cancer activity of Ruellia tuberosa on EAC induced mammary tumor
About this article
Abstract
Aim of the study was to study the antitumor effect of Ruellia tuberosa. The activity of methanolic extracts of 250, 500 mg/kg of Ruellia tuberosa leaves was evaluated against Ehrlich ascites carcinoma (EAC) tumor in mice. Acute and short-term toxicity studies were performed initially in order to ascertain the safety of methanolic extracts of Ruellia tuberosa. Tumour cells (1×106cells/mice) were injected into the right hind limb (thigh) of mammary tumour group animals subcutaneously and the tumour is allowed to develop for 11 days and the treatment is started from 12th day for a period of 20 days. The effect of methanolic extracts of Ruellia tuberosa on the growth of tumor, life span of EAC bearing hosts and simultaneous alterations in the hematological profile and histopathological profile were estimated. The methanolic extracts of Ruellia tuberosa showed decrease in tumor size, average body weight, and mean survival time thereby increasing life span of EAC tumor bearing mice. Hematological profile reverted to more or less normal levels in extracts treated mice. Histopathology has minimal effects when compared but a significant variation is seen.
References
Raju Senthil kumar, Balasubramanian Rajkapoor, Perumal Perumal, et.al. Antitumor activity of Prosopis glandulosa Torr. On Ehrlich Ascites Carcinoma (EAC) Tumor Bearing Mice. Iranian Journal of Pharmaceutical Research (2011); 10 (3):505-510.
Raju Senthil Kumar, Balasubramanian Rajkapoor, Perumal Perumal. Antitumor and Cytotoxic Activities of Methanol Extract of Indigofera linnaei Ali. Asian Pacific Journal of Cancer Prevention 2011; 12:613-618.
Meenakshi Sundaram, Satyajit Patra, Gunasingham Maniarasu. Antitumor activity of ethanol extracts of Gracilaria edulis (Gmelin) Silva on Ehrlich ascites carcinoma-bearing mice. Journal of Chineese Integrative Medicine 2012; 10(4):430-435.
Brindha Durairaj and Arthi Dorai. Evaluation of Antitumor and in vivo antioxidant potentials of Nelumbo Nucifera Gaertn (white and pink) flowers in Ehrlich Ascites Carcinoma mice. Journal of Pharmacy Research 2010;3(10):2483-2487.
Pandey CN, Medicinal Plants of Gujarat, Gujarat Ecological Education and Research Foundation, Gujarat, India, 2005.
View more references (30)
Medicinal Plants of the Guiana’s (Guyana, Surinam, French Guiana).
Chothani DL, Patel MB, Vaghasiya HU,et.al. “Review on Ruellia tuberosa (cracker plant)”. Pharmacognosy Journal 2010; 2(12) :506-512.
Suseela L and Prema S. “Pharmacognostic study on Ruellia tuberosa.” Journal of Medicinal and Aromatic Plant Sciences 2007; 29:117-122.
Reddy MB, Reddy KR and Reddy MN. “Ethnobotany of Cuddapah district, Andhra Pradesh, India.” International Journal of Pharmacognosy 1991; 29(4):273-280.
Kirtikar BD and Basu BD. Indian Medicinal Plants, vol. 3, International Book Distributors, Deheradun, India, 1935.
The Wealth Of India, A Dictionary Of Indian, Raw Material and Industrial Product, Publication and Information Directorate, Council of Scientific and Industrial Research, New Delhi, India, 1972.
Chiu NY and Chang KH. “The illustrated medicinal plants of Taiwan.” Mingtong Medical Journal 1995; 226:1.
Chen FB, Wu AB, ShiehPH,et.al. “Evaluation of the antioxidant activity of Ruellia tuberosa,” Food Chemistry 2006; 94(1):14-18.
Lans CA, Creole remedies. Case studies of ethnoveterinary medicine in Trinidad and Tobago, Ph.D.Dissertation,Wageningen University,Wageningen, The Netherlands, 2001; 2992.
[15]. Lans CA, “Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus,” Journal of Ethnobiology and Ethnomedicine 2006; 2(45):1-11.
Balick MJ, Kronenberg F, Ososki AL et al. “Medicinal plants used by latino healers for women’s health conditions in New York City,” Economic Botany 2000; 54(3):344-357.
Chen FA, Wu AB, Shieh P, Kuo DH and Hsieh CY. “Evaluation of the antioxidant activity of Ruellia tuberosa,” Food Chemistry 2006; 94(1):14-18.
Wiart C, Hannah M, Yassim M, Hamimah H and Sulaiman M. “Anti-microbial activity of Ruellia tuberosa L”. American Journal of Chinese Medicine 2005; 33(4):683-685.
Arun S, Giridharan P, Suthar A et al. Isolation of Tylocrebrine from Ruellia tuberosa through Bioassay Directed Column Chromatography and Elucidating its Anti-Cancer and Anti- Inflammatory Potential, 7th JointMeeting of GA, AFERP, ASP, PSI & SIF, Athens, Greece, 2008.
Arambewela LSR, Thambugala R and Ratnasooriya WD. “Gastroprotective activity of Ruellia tuberosa root extract in rats. Journal of TropicalMedicinal Plants 2003; 4(2):191-194.
Alam MA, Subhan N, Awal M.A. et al. “Antinociceptive and anti-inflammatory properties of Ruellia tuberosa”. Pharmaceutical Biology 2009; 47(3):209-214.
Chwan-Fwu Lin, Yu-Ling Huang, Lee-Ying Cheng, Shuenn-Jyi Sheu and Chien-Chih Chen. Bioactive flavonoids from Ruellia tuberosa. J Chin Med 2006; 17(3):103-109.
Abu-Sinna G, Esmat AM, Al-Zahaby S, et.al. Fractionation And charecterization of cerastes snake venom and the antitumor action of its lethal and non- lethal fractions. Toxicon 2003; 42:207-215.
Kuttan G, Vasudevan DM, Kuttan R. Effect of a preparation from Viscum album on tumour development in vitro and in mice. J. Ethnopharmacol 1990; 29:35-41.
D’Armour FE, Blood FR, Belden DA. The manual for laboratory work inmammalian physiology. 3rd ed. Chicago: The Uni-versity of Chicago Press; 1965.
Wintrobe MM, Lee GR, Boggs DR, Bithel TC, Athens JW, Foerester. ClinicalHematology 5th ed. Philadelphia;1961.
Ghosh MN. Toxicity studies, Fundamental of Experimental Pharmacology.Calcutta, India: Scientific book agency; 1984. Ponder B AJ., 2001- Cancer genetics. Nature, 411:336-341.
Ponder B AJ., 2001- Cancer genetics. Nature, 411:336-341.
Verweij J., and De Jong M. J. A., 2003 Achievements and future of chemotherapy. European journal of cancer, 36:1479-1487.
Talback M., Stenbeck M., Rosen M., Barlow L., and Glimelius B., 2003- Cancer survival in Sweden (1960-1998) developments across four decades. Acta oncology, 42:637-659.
Socialstyrlesn ., 2004- cancer incidence in Sweden 2003. Statistics- health anddisease, 10. Online March 2005. www.sos.se/sos/statisti.htm.
Clarkson BD, Burchenal JH. Preliminary screening of antineoplastic drugs. ProgClin Cancer 1965; 1:625-629.
Andreani A, Scapini G, Galatulas I. Potential antitumor agents IX: synthesis andantitumor activity of two analogues of Ketocaine. J. Pharm. Sci 1983; 72:814-819.
Hogland HC. Hematological complications of cancer chemotherapy. Semin Oncol 1982; 9:95-102.
Fenninger LD, Mider GB. Energy and nitrogen metabolism in cancer. Adv Cancer Res 1954; 2:229-253.